...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: ZEN-3694 and Enzalutamide 2b Trial

Bear - I wonder (maybe hope) if Newsoara returning the patents for the territories and not making the milestone payment rather making an equity investment instead speaks to keeping the company clean to deal with Merck, Astellas and Pfizer. They obviously weren't unhappy with the results to that point or they wouldn't have made the equity investment.

Share
New Message
Please login to post a reply